Non-patented intellectual property
Know-how based
Licensee
Development partner
Commercial partner
Bacterial pathogenesis can result in acute or chronic infections. Acute infections involving bacteria that exist as single, independent cells are generally treatable with antibiotics when diagnosed quickly. However, when bacteria accumulate in slime-enclosed aggregates, known as biofilms, they can acquire a certain degree of robustness and lead to chronic infections such as pneumonia in cystic fibrosis patients, chronic wounds, chronic otitis media, and implant-associated and catheter-associated infections. These biofilm-caused chronic infections often become untreatable because of their resistance to antibiotics and ability to evade immune system defenses. Currently, there is no standardized clinical assay that can detect or quantify bacterial biofilms.
Researchers at Saint Louis University have developed a quantitative biofilm assay suitable for use in the clinical setting.
The potential benefits of this technology include:
Increasing ability to assess biofilms
Increasing ability to quantify biofilm infections
Minimizing risk of misdiagnosis
Increasing the accuracy of biofilm infection diagnosis
Minimizing the time it takes to diagnosis biofilm infections
Minimizing the risk of prescribing inadequate or inappropriate treatments
The potential applications of this technology include treating various kinds of biofilm-based infections:
Catheter-associated infections
Implant-associated infections
Chronic otitis media
Chronic wounds
Pneumonia in cystic fibrosis patients
Saint Louis University is seeking partners to further develop and commercialize this technology.